Abstract
We investigated the time of onset of antituberculous drug-induced hepatotoxicity (ADIH) and related characteristics. Adult patients (n = 1,031) treated with first-line antituberculous drugs between February 2009 and January 2013 were enrolled. Of the 1,031 patients, 108 patients (10.5%) developed ADIH a mean of 39.6 ± 43.7 days after treatment initiation. Twenty-eight patients (25.9%) developed ADIH within 7 days, 73 (67.6%) within 30 days, and the rest after 30 days. The ≤ 30-day group was characterized by higher peak alanine aminotransferase (ALT) level and a high proportion of patients with maintenance of first-line antituberculous drugs compared to the > 30-day group. In subgroup analysis, the ≤ 7-day group was characterized by higher baseline aspartate aminotransferase and ALT, high proportion of patients with maintenance of first-line antituberculous drugs, and high proportion of patients with extrapulmonary tuberculosis compared to patients with ADIH that developed beyond 7 days. In multivariate analysis, serum ALT > 40 IU/L (odds ratio [OR], 2.995; 95% confidence interval [CI], 1.580 to 5.680; p = 0.001) and presence of anti-hepatitis C virus (OR, 4.204; 95% CI, 1.822 to 9.700, p = 0.001) were independent risk factors f...Continue Reading
References
Feb 1, 1996·Thorax·L P OrmerodJ Wales
Oct 1, 1996·The European Respiratory Journal·T SchabergH Lode
Jan 16, 2003·Chest·Lee McNeillPaul Cook
Feb 6, 2003·American Journal of Respiratory and Critical Care Medicine·Daphne YeeDick Menzies
Apr 2, 2003·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Yi-Shin HuangShou-Dong Lee
Nov 6, 2003·American Journal of Public Health·Melbourne F HovellAlicia Y Vera
Oct 26, 2005·Journal of Gastroenterology and Hepatology·Subhash AgalDeepak Amarapurkar
Mar 7, 2006·Respiratory Medicine·Banu Eriş GülbayTuran Acican
Aug 11, 2006·The Ceylon Medical Journal·W V SenaratneA R Wickremasinghe
Oct 6, 2006·American Journal of Respiratory and Critical Care Medicine·Jussi J SaukkonenUNKNOWN ATS (American Thoracic Society) Hepatotoxicity of Antituberculosis Therapy Subcommittee
Oct 21, 2006·Respirology : Official Journal of the Asian Pacific Society of Respirology·Wing Wai Yew, Chi Chiu Leung
Apr 5, 2008·American Journal of Respiratory and Critical Care Medicine·Kwok C ChangCheuk M Tam
Mar 3, 2009·Journal of the Formosan Medical Association = Taiwan Yi Zhi·Hsin-Yun SunKwen-Tay Luh
Jun 19, 2009·American Journal of Therapeutics·Parvaneh BaghaeiMohammadreza Masjedi
Aug 12, 2009·Hepatology International·Hoda A MakhloufHebat Alla G Rashed
May 26, 2011·PloS One·Natalie LorentJoannes Clerinx
Jul 14, 2011·PloS One·Penghui ShangSiyan Zhan
Dec 27, 2011·American Journal of Respiratory and Critical Care Medicine·Aran SinganayagamOnn Min Kon
Nov 26, 2013·Lancet·Alimuddin Zumla Baroness Masham of Ilton
Dec 3, 2013·Lung·Yuag-Meng LiuWu-Huei Hsu
Dec 25, 2013·PloS One·Nino LomtadzeHenry M Blumberg
Citations
Apr 9, 2017·Infection, Genetics and Evolution : Journal of Molecular Epidemiology and Evolutionary Genetics in Infectious Diseases·Yu WangJian-Qing He
Jun 15, 2018·Current Opinion in Allergy and Clinical Immunology·Sowmya Nagarajan, Paul Whitaker
Dec 28, 2018·BMC Infectious Diseases·Jin-Kyu ChoOk Jae Lee
May 3, 2019·Journal of the Chinese Medical Association : JCMA·Tien-En ChangMing-Chih Hou
Jul 28, 2017·Tuberculosis and Respiratory Diseases·Eunyoung HeoHee Soon Chung
Feb 9, 2019·Canadian Journal of Gastroenterology & Hepatology·Lina TaoSi-Xi Zhang
Dec 18, 2019·Respiratory Research·Jin Hwa SongJung-Kyu Lee
Sep 15, 2016·Journal of Viral Hepatitis·C TrigoL de Castro
May 29, 2020·BioMed Research International·Jude Eteneneng EnohEric Achidi Akum
Jul 6, 2019·Journal of the Chinese Medical Association : JCMA·Tien-En ChangMing-Chih Hou
Dec 29, 2020·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Hao NiuM Isabel Lucena
Jun 2, 2021·Auto- Immunity Highlights·Yolima Puentes-OsorioDaniel Taborda